Download PDF
Thromb Haemost 1971; 25(01): 157-165
DOI: 10.1055/s-0038-1654290
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Factor X

Immunological Studies
H Prydz
1   Department of Microbiology, Dental Faculty, University of Oslo, Blindern, Oslo 3, Norway
,
Å Gladhaug
1   Department of Microbiology, Dental Faculty, University of Oslo, Blindern, Oslo 3, Norway
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

A monospecific antiserum against factor X was prepared in rabbits. The antiserum precipitated factor X in human plasma and serum and monkey serum. The antiserum was used to :

1. demonstrate the presence of factor X precursor in blood from patients under anticoagulant therapy,

2. produce an artificial factor X deficiency substrate useful for testing factor X,

3. study the species specificity of factor X from various common laboratory mammals.

 

  • References

  • 1 Barnhart M. J, Anderson G. A, Baker W. V. Immunochemical studies on proteins important in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg) 08: 21 1962;
    PubMedSearch in Google Scholar
  • 2 Egeberg O. Assay of antihemophilic A, B and C factors by one-stage cephalin system. Scand. J. clin. Lab. Invest 13: 140 1961;
    CrossrefPubMedSearch in Google Scholar
  • 3 Gaarder A, Prydz H. The subcellular localization of factor VII (proconvertin) in rat liver. Biochim. biophys. Acta (Amst) 140: 545 1967;
    CrossrefPubMedSearch in Google Scholar
  • 4 Gaarder A, Prydz H. Localization of factor VII (proconvertin) in a microsomal subfraction. Biochim. biophys. Acta (Amst) 184: 220 1969;
    CrossrefPubMedSearch in Google Scholar
  • 5 Ganrot P. O, Niléhn J. E. Plasma prothrombin during treatment with Dicumarol. II. Demonstration of an abnormal prothrombin fraction. Scand. J. clin. Lab. Invest 22: 23 1968;
    PubMedSearch in Google Scholar
  • 6 Gladhaug Å, Prydz H. Purification of the coagulation factors VII and X from human serum. Some properties of factor VII. Biochim. biophys. Acta (Amst) 215: 105 1970;
    CrossrefPubMedSearch in Google Scholar
  • 7 Hemker H. C, Muller A. D. Kinetic aspects of the interaction of blood-clotting enzymes VI. Localization of the site of blood-coagulation inhibition by the Protein Induced by Vitamin K Absence (PIVKA). Thrombos. Diathes. haemorrh. (Stuttg) 20: 78 1968;
    PubMedSearch in Google Scholar
  • 8 Hemker H. C, Veltkamp J. J, Hensen A, Loeliger E. A. Nature of prothrombin biosynthesis : Preprothrombinaemia in vitamin K-deficiency. Nature 200: 589 1963;
    CrossrefPubMedSearch in Google Scholar
  • 9 Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand. J. clin. Lab. Invest. 09. Suppl.27 1957
    PubMedSearch in Google Scholar
  • 10 Jackson G. M, Hanahan D. J. Studies on bovine factor X. II. Characterization of purified factor X. Observations on some alterations in zone electrophoretic and chromatographic behavior occurring during purification. Biochemistry 07: 4506 1968;
    CrossrefPubMedSearch in Google Scholar
  • 11 Josso F, Lavergne J. M, Gouault M, Prou-Wartelle O, Soulier J. P. Différents états moléculaires du facteur II (prothrombine). Leur étude â l’aide de la staphylocoagulase et d’anticorps anti-facteur II. I. Le facteur II chez les sujets traités par les antagonistes de la vitamine K. Thrombos. Diathes. haemorrh. (Stuttg) 20: 88 1968;
    PubMedSearch in Google Scholar
  • 12 Josso F, Lavergne J. M, Weilland G, Soulier J. P. Etude immunologique de la prothrombine et de la thrombine humaines. Thrombos. Diathes. haemorrh. (Stuttg) 18: 311 1967;
    PubMedSearch in Google Scholar
  • 13 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. Protein measurements with the Folin phenol reagent. J. biol. Chem 193: 265 1951;
    PubMedSearch in Google Scholar
  • 14 Niléhn J. E, Ganrot P. O. Plasma prothrombin during treatment with Dicumarol. I. Immunochemical determination of its concentration in plasma. Scand. J. clin. Lab. Invest 22: 17 1968;
    CrossrefPubMedSearch in Google Scholar
  • 15 Owren P. A, Aas K. The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 03: 201 1951;
    CrossrefPubMedSearch in Google Scholar
  • 16 Prydz H. Studies on proconvertin (Factor VII). IV. The adsorption on barium sulphate. Scand. J. clin. Lab. Invest 16: 409 1964;
    CrossrefPubMedSearch in Google Scholar
  • 17 Prydz H. Studies on proconvertin (Factor VII). V. Biosynthesis in suspension cultures of rat liver cells. Scand. J. clin. Lab. Invest 16: 540 1964;
    CrossrefPubMedSearch in Google Scholar
  • 18 Prydz H. Studies on proconvertin (Factor VII). VI. The production in rabbits of an antiserum against factor VII. Scand. J. clin. Lab. Invest 17: 66 1965;
    CrossrefPubMedSearch in Google Scholar
  • 19 Prydz H. Studies on proconvertin (Factor VII). IX. Some characteristics of purified factor VII preparations. Scand. J. clin. Lab. Invest 17 Suppl. 84 78 1965;
    PubMedSearch in Google Scholar
  • 20 Prydz H, Fossen R. A. Studies on proconvertin (Factor VII). VIII. The species specificity of factor VII. Scand. J. clin. Lab. Invest 17: 218 1965;
    CrossrefPubMedSearch in Google Scholar
  • 21 Prydz H, Gaudernack G. Studies on the biosynthesis of factor VII (proconvertin). The mode of action of warfarin. Biochim. biophys. Acta (Amst) 230: 373 1971;
    CrossrefPubMedSearch in Google Scholar
  • 22 Prydz H, Gladhaug Å. A specific system for the estimation of prothrombin activity. Thrombos. Diathes. haemorrh. (Stuttg). (In press.)
    PubMed